AUS
NZ
UK
CA
USA
IND
Faron Pharmaceuticals Limited (LSE:FARN) has received fast-track approval from the US Food and Drug Administration (FDA) for its leading drug candidate, bexmarilimab, intended to treat relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine.
The FDA grants fast-track designation to products aimed at treating serious or life-threatening conditions with the potential to address an unmet medical need. This designation allows Faron to work closely with the FDA throughout the drug development process, potentially accelerating the path to market approval.
Faron’s chief executive, Juho Jalkanen, emphasized the significance of this development, noting that it underscores the urgent need for new treatment options beyond hypomethylating agents (HMAs) for higher-risk MDS. The approval also strengthens the case for bexmarilimab's ability to overcome resistance to HMAs.
Petri Bono, Faron’s chief medical officer, highlighted the seriousness of r/r MDS as a life-threatening condition with limited treatment options, stressing the high unmet medical need in this area. Bono noted that clinical trial results have demonstrated bexmarilimab's ability to induce deep, clinically meaningful responses in patients who have not responded to HMAs. The FDA fast-track designation enhances bexmarilimab's position as a potential cornerstone treatment for r/r MDS and will support its development towards full market approval.
This recognition also reflects the broader potential of myeloid cell reprogramming in overcoming resistance and activating the immune system in treating various haematological and solid tumors.
In a recent trading update for the first half of the year, Faron reported that preliminary data from the Phase II bexmarilimab trial confirmed the positive results observed in Phase I for MDS patients who had failed treatment with HMAs. Among 14 patients treated with the combination of bexmarilimab and azacitidine, an overall response rate of 79% was observed.
Faron’s financial position was notably strengthened in the first half of the year, with €35.5 million raised through a convertible loan issuance and two share placements, leaving a cash balance of €30 million as of June 30. This bolstered financial status supports the ongoing development and potential market launch of bexmarilimab.
